rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
Recruiting · Early phase 1 · NCT05852041
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
At a glance
- Research payments reported, 2025
- $106,382
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- Northwestern University (with National Cancer Institute (NCI))
- Tested
- Biopsy of Prostate (procedure), Decipher Prostate Cancer Test (genetic), Flotufolastat F-18 Gallium (other), Magnetic Resonance Imaging (procedure), Multiparametric Magnetic Resonance Imaging (procedure), Positron Emission Tomography (procedure), Radical Prostatectomy (procedure)
- Dates
- Started 2023-06-07; completion 2035-06-07
- Results posted
- Not yet
This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer who are candidates for active surveillance. A PET scan is a test that uses a radioactive drug and a computer to create images of how organs and tissues in the body are functioning. The radioactive drug used in this study, rhPSMA-7.3, attaches to the abnormal cells in the body at a different rate than normal cells which allows the scanner to create a detailed picture of how the body is wo…
From ClinicalTrials.gov, last updated 2026-07-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $106,382 in research payments for this study in 2025 (21 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Northwestern University $106,382
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.